Accurate and reproducible.
Biomarker flexibility.
Logistics and workflow convenience.

Clinical trial CTC monitoring

Serial monitoring of circulating tumor cell (CTC) numbers and biomarker expression levels provides critical insight into cancer drug efficacy and pharmacodynamics.

Designed for CTC monitoring in global clinical trials, RareCyte’s products and services provide a sample-to-result workflow that accurately and reproducibly phenotypes as few as 1 CTC per tube of blood.

Phenotype CTCs with Confidence

RareCyte CTC assays cover an expansive range of biomarkers and indications, powered by RarePlex technology.

• Rapid and flexible assay development and validation
• Visual CTC confirmation assisted by ML/AI scoring system
• Quantification of multiple biomarkers that inform response to therapy
• Option for downstream single CTC genomic analysis

CTC testing workflow designed for convenient clinical trial logistics

RareCyte’s Liquid Biopsy platform enables deployment of high-performance CTC assays for global clinical trials.

• Scalable, high-capacity, blood draw-to-result platform
• 7-day blood stability enables global shipment from hospitals to processing centers
• 3-year slide stability for sample banking and batch testing

• Automated staining, scanning, and scoring
• Assay-specific scoring models ensure reviewer concordance
• Deploy through our global CRO network

AccuCyte® sample preparation system

Simple and repeatable system that transfers nucleated cells from blood to slides with virtually no cell loss.

RarePlex® CTC assays

Up to 5-plex customizable panels, designed for autostainers, for identification and classification of rare cells.

CyteFinder imaging systems

Automated LIMS-compatible fluorescent imaging systems with integrated machine learning to identify rare cells.

Options

• 80-slide capacity for 24/7 unattended scanning
• CytePicker® retrieval module for single cell genomic analysis